eligibility_summary
Include: Women 18–70 with recurrent/metastatic TNBC (ER/PR<1%, HER2−), ECOG 0–1, survival ≥3 months, measurable disease, adequate organs, ≥3‑week washout. Stage II: no advanced systemic therapy and paclitaxel‑free interval >6 months or never used. Stage I: ≥1 prior systemic line. Exclude: CNS mets, heart disease, neuropathy >G1, unresolved AEs, recent major surgery, pregnancy, other cancers, malabsorption, uncontrolled effusions, recent trials, unhealed wounds, active HBV/HCV, drug/mAb allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
FUTURE-Trop2 (Phase I/II) is an umbrella, first-line study in metastatic/locally advanced TNBC testing TROP2-directed sacituzumab govitecan (SG, anti-TROP2 antibody–drug conjugate delivering SN-38, a topoisomerase I inhibitor) alone or combined per molecular subtype: • LAR subtype: SG + SHR3680 (nonsteroidal androgen receptor antagonist, blocks AR signaling) vs SG alone. Targets: TROP2+ tumor cells, AR pathway. • IM subtype: SG + SHR1210 (camrelizumab, anti–PD-1 monoclonal antibody) vs SG alone. Targets: TROP2+ tumor cells, PD-1/PD-L1 immune checkpoint to activate T cells. • BLIS subtype: SG + SHR3162 (fluzoparib, PARP inhibitor) vs SG alone. Targets: TROP2+ cells, DNA damage response via PARP, exploiting HR deficiencies. • MES subtype: SG + VEGFRI (BP102, VEGF/VEGFR pathway inhibitor, anti-angiogenic) vs SG alone. Targets: TROP2+ cells, tumor angiogenesis via VEGF/VEGFR signaling.